Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 12NIH 3INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 261Neoplasms 143Breast Neoplasms 140Colorectal Neoplasms 124Prostatic Neoplasms 94Neoplasm Metastasis 93Multiple Myeloma 92Ovarian Neoplasms 91Lung Neoplasms 86Squamous Cell Carcinoma of Head and Neck 62Pancreatic Neoplasms 62Recurrence 59Endometrial Neoplasms 55Melanoma 52Small Cell Lung Carcinoma 51Leukemia, Lymphocytic, Chronic, B-Cell 48Stomach Neoplasms 47Carcinoma, Renal Cell 46Leukemia, Myeloid, Acute 44Lymphoma, Non-Hodgkin 40Advanced Solid Tumors 39Urinary Bladder Neoplasms 37Triple Negative Breast Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 36Lymphoma, Large B-Cell, Diffuse 36Head and Neck Neoplasms 36Carcinoma, Hepatocellular 35Lymphoma, Follicular 30Esophageal Neoplasms 30Myasthenia Gravis 27

Interventions

Midazolam 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Biphenotypic, Acute × 30 days × Clear all
NCT03802695 2026-06-02

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Orca Biosystems, Inc.

Phase 1 Recruiting
300 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡